Graphene oxide-iron oxide nanocomposite as an inhibitor of Aβ 42 amyloid peptide aggregation.

Inhibiting amyloid β (Aβ) aggregation has drawn much attention because it is one of the main reasons for the cause of Alzheimer's disease (AD). Here we have synthesized a nanocomposite of graphene oxide-iron oxide (GOIO) and demonstrated its ability of modulating Aβ aggregation. The inhibition effects of the GOIO nanocomposite on Aβ aggregates was studied by Thioflavin T fluorescence assay, circular dichroism and transmission electron microscopy, respectively. Furthermore, the cell viability study revealed that the GOIO nanocomposite can reduce the toxicity of Aβ fibrils to neuroblastoma cells. Our results demonstrated that the combination of GO and IO as a nanocomposite material has a potential use for the design new therapeutic agents for the treatment of Alzheimer's disease.